SCHEMBL680497

SCHEMBL680497

O=[N+]([O-])c1ccc(Oc2cc3cn[nH]c3cc2Br)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.55
LMNA P02545 3/20 0.55
NOS1 P29475 2/20 0.55
POLB P06746 2/20 0.55
CYP3A4 P08684 1/20 0.55
ALOX15 P16050 1/20 0.55
MAOB P27338 1/20 0.55
AXL P30530 1/20 0.45
HTT P42858 2/20 0.43
HSPB1 P04792 3/20 0.42
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41
RAB9A P51151 1/20 0.40
ATM Q13315 1/20 0.39
MEN1 O00255 2/20 0.39
ALDH1A1 P00352 2/20 0.39
KMT2A Q03164 2/20 0.39
PDE7A Q13946 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680304 0.83 MAPT (0.53) MAPTLMNANOS1POLBCYP3A4
SCHEMBL27975732 0.80 MAPT (0.70) MAPTLMNANOS1POLBCYP3A4
SCHEMBL681119 0.73 ATM (0.54) MAPTLMNAHTTHSPB1RAB9A
SCHEMBL3483763 0.73 MAPT (0.63) MAPTLMNANOS1POLBCYP3A4
SCHEMBL13288378 0.73 MAPT (0.63) MAPTLMNANOS1POLBCYP3A4
SCHEMBL13288379 0.73 MAPT (0.63) MAPTLMNANOS1POLBCYP3A4
SCHEMBL2880077 0.73 MAPT (0.63) MAPTLMNANOS1POLBCYP3A4
SCHEMBL16751174 0.72 NOS1 (0.53) MAPTLMNANOS1POLBCYP3A4
SCHEMBL271522 0.72 MAPT (1.00) MAPTLMNANOS1POLBCYP3A4
SCHEMBL148826 0.72 NOS1 (1.00) MAPTLMNANOS1POLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC MAPT 4502/4885LMNA 4448/4885NOS1 2168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.